Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4761655 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL916010 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL589886 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL14134551 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL588927 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL24974550 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12081887 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL22444953 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL21224008 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL31671113 | 1.00 | HPGD (0.40) | HPGDHTTSMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120148631-A1 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-06-14 | — | — | US | disclosed |
| US-20110142886-A1 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142886-A1 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | PARN, PUF60, PARG | HPGD 2246/4885HTT 279/4885SMN1; SMN2 1491/4885 |
| US-20120148631-A1 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | PARN, PUF60, PARG | HPGD 2246/4885HTT 279/4885SMN1; SMN2 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.